Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 133 of 1,261
  1. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Agios Pharmaceuticals, Inc. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  2. US 11919933

    Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease

    GUANGDONG BEATING ORIGIN REGENERATIVE MEDICINE CO., LTD. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  3. US 11919868

    Heterocyclic compounds and related methods

    Recursion Pharmaceuticals, Inc. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  4. US 11919836

    Prodrugs of fencamfamine

    Praxis Bioresearch, LLC Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  5. US 11919887

    Substituted tetrahydrofurans as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  6. US 11919937

    T cell receptors for immunotherapy

    The Board of Regents of the University of Texas System Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  7. US 11918654

    Solid solution compositions and use in severe pain

    Infirst Healthcare Limited Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  8. US 11918660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  9. US 11919880

    HCV protease inhibitors

    The Regents of the University of California Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  10. US 11919888

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  11. US 11919896

    [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof

    ZHUHAI UNITED LABORATORIES CO., LTD. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  12. US 11918638

    Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  13. US 11918633

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

    BIOMARIN PHARMACEUTICAL INC. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  14. US 11918686

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    The Regents of the University of California Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  15. US 11918571

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  16. US 11918622

    Ready-to-use bivalirudin compositions

    MAIA PHARMACEUTICALS, INC. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  17. US 11918568

    Fused ring compound having urea structure

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  18. US 11918770

    Implants for localized drug delivery and methods of use thereof

    The Regents of the University of California Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  19. US 11918563

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  20. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  21. US 11918557

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  22. US 11918642

    HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Mar 5, 2024 Β· Expires Feb 29, 2044

    granted
  23. AU 2022323463

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] Β· Granted Feb 29, 2024 Β· Expires Feb 24, 2044

    granted
  24. US 11912762

    Method of treating osteoarthritis by administering an anti-connexin 43 antibody

    The Board of Regents of the University of Texas System Β· Granted Feb 27, 2024 Β· Expires Feb 22, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.